Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Gastroenterology · N Engl J Med · 2026-11-05
RCTn = 757
Watts et al. Plozasiran for Severe Hypertriglyceridemia and Risk of PancreatitisGastroenterology · Gastroenterology · 2026-11-01
Guideline
Levy et al. AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary CholangitisGastroenterology · N Engl J Med · 2026-10-15
RCTn = 252
Abreu et al. Phase 2 Trial of Icotrokinra for Patients with Ulcerative ColitisGastroenterology · Lancet · 2026-09-30
RCTn = 880
Goel et al. 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in IndiaGastroenterology · Gastroenterology · 2026-09-30
Guideline
Rex et al. Serrated Polyposis Syndrome: A Review and Consensus Statement by the US Multi-Society Task Force on Colorectal CancerGastroenterology · Lancet Gastroenterol Hepatol · 2026-09-23
RCTn = 428
Yaqub et al. Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trialGastroenterology · Lancet Gastroenterol Hepatol · 2026-09-11
RCTn = 386
Noor et al. Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trialGastroenterology · Lancet Gastroenterol Hepatol · 2026-09-03
Meta-analysisn = 6,925
Mannucci et al. Germline multigene panel testing for colorectal cancer: a systematic review and meta-analysisGastroenterology · Lancet Gastroenterol Hepatol · 2026-08-26
RCTn = 102
Loomba et al. ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trialGastroenterology · Lancet Gastroenterol Hepatol · 2026-08-25
RCTn = 342
Kudo et al. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial